Jaworska Natalia, Makuk Kira, Krewulak Karla D, Niven Daniel J, Ismail Zahinoor, Burry Lisa D, Mehta Sangeeta, Fiest Kirsten M
Department of Critical Care Medicine, University of Calgary, Calgary, AB, Canada.
Alberta Health Services, Calgary, AB, Canada.
Crit Care Explor. 2022 Dec 1;4(12):e0806. doi: 10.1097/CCE.0000000000000806. eCollection 2022 Dec.
Antipsychotic medications are frequently prescribed to critically ill patients leading to their continuation at transitions of care thereafter. The aim of this study was to generate evidence-informed consensus statements with key stakeholders on antipsychotic minimization and deprescribing for ICU patients.
We completed three rounds of surveys in a National modified Delphi consensus process. During rounds 1 and 2, participants used a 9-point Likert scale (1-strongly disagree, 9-strongly agree) to rate perceptions related to antipsychotic prescribing (i.e., experiences regarding delivery of patient care), knowledge and frequency of antipsychotic use, knowledge surrounding antipsychotic guideline recommendations, and strategies (i.e., interventions addressing current antipsychotic prescribing practices) for antipsychotic minimization and deprescribing. Consensus was defined as a median score of 1-3 or 7-9. During round 3, participants ranked statements on antipsychotic minimization and deprescribing strategies that achieved consensus (median score 7-9) using a weighted ranking scale (0-100 points) to determine priority.
Online surveys distributed across Canada.
Fifty-seven stakeholders (physicians, nurses, pharmacists) who work with ICU patients.
None.
Participants prioritized six consensus statements on strategies for consideration when developing and implementing interventions to guide antipsychotic minimization and deprescribing. Statements focused on limiting antipsychotic prescribing to patients: 1) with hyperactive delirium, 2) at risk to themselves, their family, and/or staff due to agitation, and 3) whose care and treatment are being impacted due to agitation or delirium, and prioritizing 4) communication among staff about antipsychotic effectiveness, 5) direct and efficient communication tools on antipsychotic deprescribing at transitions of care, and 6) medication reconciliation at transitions of care.
We engaged diverse stakeholders to generate evidence-informed consensus statements regarding antipsychotic prescribing perceptions and practices that can be used to implement interventions to promote antipsychotic minimization and deprescribing strategies for ICU patients with and following critical illness.
抗精神病药物经常被开给重症患者,导致他们在后续的护理过渡阶段仍继续使用。本研究的目的是与关键利益相关者就重症监护病房(ICU)患者的抗精神病药物最小化和减药问题达成基于证据的共识声明。
我们在全国改良德尔菲共识过程中完成了三轮调查。在第1轮和第2轮中,参与者使用9点李克特量表(1 - 强烈不同意,9 - 强烈同意)对与抗精神病药物处方相关的认知(即患者护理提供方面的经验)、抗精神病药物使用的知识和频率、抗精神病药物指南建议的知识以及抗精神病药物最小化和减药的策略(即解决当前抗精神病药物处方实践的干预措施)进行评分。共识被定义为中位数分数为1 - 3或7 - 9。在第3轮中,参与者使用加权排名量表(0 - 100分)对关于抗精神病药物最小化和减药策略且已达成共识(中位数分数7 - 9)的声明进行排名,以确定优先级。
在加拿大各地进行在线调查。
57名与ICU患者打交道的利益相关者(医生、护士、药剂师)。
无。
参与者对在制定和实施指导抗精神病药物最小化和减药的干预措施时应考虑的六项策略共识声明进行了优先级排序。声明重点关注将抗精神病药物处方限制于以下患者:1)患有多动谵妄的患者,2)因躁动对自己、家人和/或工作人员构成风险的患者,3)因躁动或谵妄而其护理和治疗受到影响的患者,以及优先考虑4)工作人员之间关于抗精神病药物有效性的沟通,5)在护理过渡阶段关于抗精神病药物减药的直接且有效的沟通工具,6)护理过渡阶段的药物重整。
我们让不同的利益相关者参与,就抗精神病药物处方认知和实践达成基于证据的共识声明,这些声明可用于实施干预措施,以促进对患有重症疾病及重症疾病后的ICU患者的抗精神病药物最小化和减药策略。